Uso de bloqueadores-β y la incidencia de exacerbaciones de la enfermedad obstructiva pulmonar crónica

Translated title of the contribution: β-blocker use and incidence of chronic obstructive pulmonary disease exacerbations

Michelle Z. Farland, Cassey J. Peters, Juli Williams, Kenneth Bielak, Robert Heidel, Shaunta' Chamberlin

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: β-Adrenergic antagonist (β-blocker) use in patients with chronic obstructive pulmonary disease (COPD) has been avoided as a result of potential risk of pulmonary adverse effects. However, recent studies indicate that β-blocker use in patients with COPD can decrease outpatient visits and either decrease or have no effect on the number of hospitalizations. Long-term treatment with β-blockers has been shown to increase survival and decrease exacerbations in patients with COPD. Objective: To assess the impact of β-blocker use on the incidence of exacerbations in patients with COPD. Methods: In a retrospective cohort study of patients with COPD from 2 academic primary care practice sites who were seen in 2010, patients were identified using International Classification of Diseases, 9th revision, Clinical Modification codes for COPD and reviewing active medication lists for COPD-specific medications (tiotropium). Patients were classified as either a β-blocker user or a nonuser. Primary outcomes were incidence and severity of COPD exacerbations. Secondary outcomes included COPD exacerbations distinguished by β-blocker cardioselectivity and all-cause hospitalizations. Results: The study enrolled 412 patients. Of those, 166 patients were β-blocker users and 246 were β-blocker nonusers. β-Blocker users were less likely to have a COPD exacerbation (OR 0.61, 95% CI 0.40-0.93) and had fewer mild exacerbations (OR 0.56; 95% CI 0.34-0.89). There was no significant difference in COPD exacerbations based on β-blocker cardioselectivity (OR 0.84, 95% CI 0.38-1.83). When controlled for, using a backwards stepwise logistic regression, β-blocker use was a variable in the model that predicted exacerbations but alone was not statistically significant (adjusted OR 0.62, 95% CI 0.39-1.01). Conclusions: Patients with COPD prescribed a β-blocker were significantly less likely to have a COPD exacerbation and had fewer mild COPD exacerbations.

Original languageSpanish
Pages (from-to)651-656
Number of pages6
JournalAnnals of Pharmacotherapy
Volume47
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Chronic Obstructive Pulmonary Disease
Disease Progression
Incidence
Adrenergic Antagonists
Hospitalization
International Classification of Diseases
Primary Health Care
Cohort Studies
Outpatients
Retrospective Studies
Logistic Models

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Cite this

Uso de bloqueadores-β y la incidencia de exacerbaciones de la enfermedad obstructiva pulmonar crónica. / Farland, Michelle Z.; Peters, Cassey J.; Williams, Juli; Bielak, Kenneth; Heidel, Robert; Chamberlin, Shaunta'.

In: Annals of Pharmacotherapy, Vol. 47, No. 5, 01.05.2013, p. 651-656.

Research output: Contribution to journalArticle

@article{8b2461febbb64fc5abdbb074547e401e,
title = "Uso de bloqueadores-β y la incidencia de exacerbaciones de la enfermedad obstructiva pulmonar cr{\'o}nica",
abstract = "Background: β-Adrenergic antagonist (β-blocker) use in patients with chronic obstructive pulmonary disease (COPD) has been avoided as a result of potential risk of pulmonary adverse effects. However, recent studies indicate that β-blocker use in patients with COPD can decrease outpatient visits and either decrease or have no effect on the number of hospitalizations. Long-term treatment with β-blockers has been shown to increase survival and decrease exacerbations in patients with COPD. Objective: To assess the impact of β-blocker use on the incidence of exacerbations in patients with COPD. Methods: In a retrospective cohort study of patients with COPD from 2 academic primary care practice sites who were seen in 2010, patients were identified using International Classification of Diseases, 9th revision, Clinical Modification codes for COPD and reviewing active medication lists for COPD-specific medications (tiotropium). Patients were classified as either a β-blocker user or a nonuser. Primary outcomes were incidence and severity of COPD exacerbations. Secondary outcomes included COPD exacerbations distinguished by β-blocker cardioselectivity and all-cause hospitalizations. Results: The study enrolled 412 patients. Of those, 166 patients were β-blocker users and 246 were β-blocker nonusers. β-Blocker users were less likely to have a COPD exacerbation (OR 0.61, 95{\%} CI 0.40-0.93) and had fewer mild exacerbations (OR 0.56; 95{\%} CI 0.34-0.89). There was no significant difference in COPD exacerbations based on β-blocker cardioselectivity (OR 0.84, 95{\%} CI 0.38-1.83). When controlled for, using a backwards stepwise logistic regression, β-blocker use was a variable in the model that predicted exacerbations but alone was not statistically significant (adjusted OR 0.62, 95{\%} CI 0.39-1.01). Conclusions: Patients with COPD prescribed a β-blocker were significantly less likely to have a COPD exacerbation and had fewer mild COPD exacerbations.",
author = "Farland, {Michelle Z.} and Peters, {Cassey J.} and Juli Williams and Kenneth Bielak and Robert Heidel and Shaunta' Chamberlin",
year = "2013",
month = "5",
day = "1",
doi = "10.1345/aph.1R600",
language = "Spanish",
volume = "47",
pages = "651--656",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "5",

}

TY - JOUR

T1 - Uso de bloqueadores-β y la incidencia de exacerbaciones de la enfermedad obstructiva pulmonar crónica

AU - Farland, Michelle Z.

AU - Peters, Cassey J.

AU - Williams, Juli

AU - Bielak, Kenneth

AU - Heidel, Robert

AU - Chamberlin, Shaunta'

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Background: β-Adrenergic antagonist (β-blocker) use in patients with chronic obstructive pulmonary disease (COPD) has been avoided as a result of potential risk of pulmonary adverse effects. However, recent studies indicate that β-blocker use in patients with COPD can decrease outpatient visits and either decrease or have no effect on the number of hospitalizations. Long-term treatment with β-blockers has been shown to increase survival and decrease exacerbations in patients with COPD. Objective: To assess the impact of β-blocker use on the incidence of exacerbations in patients with COPD. Methods: In a retrospective cohort study of patients with COPD from 2 academic primary care practice sites who were seen in 2010, patients were identified using International Classification of Diseases, 9th revision, Clinical Modification codes for COPD and reviewing active medication lists for COPD-specific medications (tiotropium). Patients were classified as either a β-blocker user or a nonuser. Primary outcomes were incidence and severity of COPD exacerbations. Secondary outcomes included COPD exacerbations distinguished by β-blocker cardioselectivity and all-cause hospitalizations. Results: The study enrolled 412 patients. Of those, 166 patients were β-blocker users and 246 were β-blocker nonusers. β-Blocker users were less likely to have a COPD exacerbation (OR 0.61, 95% CI 0.40-0.93) and had fewer mild exacerbations (OR 0.56; 95% CI 0.34-0.89). There was no significant difference in COPD exacerbations based on β-blocker cardioselectivity (OR 0.84, 95% CI 0.38-1.83). When controlled for, using a backwards stepwise logistic regression, β-blocker use was a variable in the model that predicted exacerbations but alone was not statistically significant (adjusted OR 0.62, 95% CI 0.39-1.01). Conclusions: Patients with COPD prescribed a β-blocker were significantly less likely to have a COPD exacerbation and had fewer mild COPD exacerbations.

AB - Background: β-Adrenergic antagonist (β-blocker) use in patients with chronic obstructive pulmonary disease (COPD) has been avoided as a result of potential risk of pulmonary adverse effects. However, recent studies indicate that β-blocker use in patients with COPD can decrease outpatient visits and either decrease or have no effect on the number of hospitalizations. Long-term treatment with β-blockers has been shown to increase survival and decrease exacerbations in patients with COPD. Objective: To assess the impact of β-blocker use on the incidence of exacerbations in patients with COPD. Methods: In a retrospective cohort study of patients with COPD from 2 academic primary care practice sites who were seen in 2010, patients were identified using International Classification of Diseases, 9th revision, Clinical Modification codes for COPD and reviewing active medication lists for COPD-specific medications (tiotropium). Patients were classified as either a β-blocker user or a nonuser. Primary outcomes were incidence and severity of COPD exacerbations. Secondary outcomes included COPD exacerbations distinguished by β-blocker cardioselectivity and all-cause hospitalizations. Results: The study enrolled 412 patients. Of those, 166 patients were β-blocker users and 246 were β-blocker nonusers. β-Blocker users were less likely to have a COPD exacerbation (OR 0.61, 95% CI 0.40-0.93) and had fewer mild exacerbations (OR 0.56; 95% CI 0.34-0.89). There was no significant difference in COPD exacerbations based on β-blocker cardioselectivity (OR 0.84, 95% CI 0.38-1.83). When controlled for, using a backwards stepwise logistic regression, β-blocker use was a variable in the model that predicted exacerbations but alone was not statistically significant (adjusted OR 0.62, 95% CI 0.39-1.01). Conclusions: Patients with COPD prescribed a β-blocker were significantly less likely to have a COPD exacerbation and had fewer mild COPD exacerbations.

UR - http://www.scopus.com/inward/record.url?scp=84877095853&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877095853&partnerID=8YFLogxK

U2 - 10.1345/aph.1R600

DO - 10.1345/aph.1R600

M3 - Article

VL - 47

SP - 651

EP - 656

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 5

ER -